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https://doi.org/10.1016/j.str.2021.03.001SUMMARYBranched Lipid II, required for the formation of indirectly crosslinked peptidoglycan, is generated byMurM, a
protein essential for high-level penicillin resistance in the human pathogen Streptococcus pneumoniae. We
have solved the X-ray crystal structure of Staphylococcus aureus FemX, an isofunctional homolog, and have
used this as a template to generate a MurM homology model. Using this model, we performmolecular dock-
ing and molecular dynamics to examine the interaction of MurM with the phospholipid bilayer and the mem-
brane-embedded Lipid II substrate. Our model suggests that MurM is associated with the major membrane
phospholipid cardiolipin, and experimental evidence confirms that the activity of MurM is enhanced by this
phospholipid and inhibited by its direct precursor phosphatidylglycerol. The spatial association of pneumo-
coccal membrane phospholipids and their impact on MurM activity may therefore be critical to the final ar-
chitecture of peptidoglycan and the expression of clinically relevant penicillin resistance in this pathogen.INTRODUCTION
The peptidoglycan (PG) of the bacterial cell wall is a polymer
consisting of alternating b-1,4-linked N-acetyl glucosamine
(GlcNAc) and N-acetyl muramic acid (MurNAc) residues. Ap-
pended to the MurNAc sugar is a pentapeptide stem that can
be crosslinked directly or indirectly to form a rigid mesh-like
structure (Bugg et al., 2011). PG biosynthesis begins with the
cytoplasmic formation of a Park nucleotide, which is subse-
quently converted into a lipid-linked PG precursor known as
Lipid II. Lipid II is then transported across the membrane, where
it is polymerized and crosslinked by the penicillin-binding pro-
teins (PBPs) (Figure 1). PG is an essential component of the
cell wall, involved in cell growth and division, maintaining struc-
tural integrity, and resisting high osmotic pressures. Inhibition of
cell wall biosynthesis is a key mechanism for many antibiotics,
including b-lactams, glycopeptides, and amino acid analogs
(Schneider and Sahl, 2010).
InStreptococcus pneumoniae and other Gram-positive bacte-
ria, the glutamate at the second position of the Lipid II pentapep-
tide is a-amidated to form iso-glutamine by the essential GatT/
MurD complex (Figueiredo et al., 2012; M€unch et al., 2012; Za-
pun et al., 2013; Morlot et al., 2018). In addition, branched LipidStructure 29, 731–74
This is an open access article under the CC BY-NII, capable of generating indirect crosslinks, can be formed by
the non-essential aminoacyl-tRNA-dependent ligases, MurM
and MurN. MurM and MurN are responsible for the sequential
addition of amino acids to the third-position lysine of the penta-
peptide stem of Lipid II (Filipe et al., 2000). MurM can append
either L-serine or L-alanine at the first position of the dipeptide
bridge, while MurN extends this modification by addition of an
invariable L-alanyl moiety. Branched PG precursors are also
found in several other Gram-positive bacterial pathogens, for
example the glycyl-tRNAGly-dependent enzymes FemX, FemA,
and FemB are responsible for the addition of a pentaglycyl
bridge inStaphylococcus aureus (Schneider et al., 2004). In com-
parison with other Gram-positive organisms, the PG of S. pneu-
moniae is highly heterogeneous: the predominant C-terminal
amino acid at position 1 of the dipeptide and the proportion of in-
direct crosslinks throughout the PG vary significantly between
different strains (Severin and Tomasz, 1996; Garcia-Bustos
et al., 1987;Garcia-Bustos and Tomasz, 1990). In vitro and in vivo
studies indicate that MurM from the penicillin-resistant strain S.
pneumoniae(159) preferentially incorporates L-alanine, while
MurM from a penicillin-sensitive strain S. pneumoniae(Pn16)
preferentially incorporates L-serine (Lloyd et al., 2008). In addi-
tion, penicillin-resistant strains demonstrated higher levels of2, July 1, 2021 ª 2021 The Authors. Published by Elsevier Ltd. 731
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. The PG biosynthesis pathway
(1) The cytoplasmic stage is characterized by the formation of UDP-MurNAc-pentapeptide (UDP-MurNAc-5P) by MurA-MurF. The pentapeptide stem peptide
usually comprises L-Ala-g-D-Glu-L-Lys-D-Ala-D-Ala in most Gram-positive organisms including the pneumococcus.
(2) At the internal face of the cytoplasmic membrane, MraY catalyzes the formation of Lipid I from UDP-MurNAc-5P to undecaprenyl-pyrophosphate, which is
then converted to Lipid II by MurG. In S. pneumoniae, the second position D-glutamyl a-carboxyl is amidated to D-iso-glutamine (iGln) by the MurT/GatD
complex, and in some cases a dipeptide branch of either L-Ser/L-Ala or L-Ala/L-Ala may be appended at the ε-amino group of the third-position lysine by MurM
and MurN, respectively. The exact order of the cytoplasmic membrane steps remains uncertain, but here for clarity they appear as a linear sequence, with
conversion to Lipid II occurring before peptide stem modifications, and amidation occurring before branching. Lipid II is translocated across the membrane
by MurJ.
(3) At the external face of the cytoplasmicmembrane, class A PBPs and complexes of SEDs-Class B PBPs form glycan chains by transglycosylation (TG), with the
concomitant release of undecaprenyl-pyrophosphate, and form either direct or indirect crosslinks throughout the PG layer via transpeptidation (TP). Nucleotide
sugars UDP-GlcNAc andUDP-MurNAc and the sugars GlcNAc andMurNAc are signified by blue, violet, dark-blue, and purple elongated hexagons, respectively.
Figure created using BioRender.com.
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OPEN ACCESS Articleindirect crosslinking in the PG compared with penicillin-suscep-
tible isolates, although the overall degree of crosslinking re-
mained constant (Garcia-Bustos and Tomasz, 1990).
Resistance to b-lactam antibiotics in S. pneumoniae is char-
acterized by extensive interspecies recombination of PBP
transpeptidase domains, which results in sequence heteroge-
neity within and around the mosaic PBP active site with a
consequential lowering of b-lactam binding affinity (Smith
et al., 1991). This mechanism of resistance contrasts with
that of many other bacteria that have acquired genes for
b-lactamase enzymes which inactivate the antibiotic before
it binds to and inhibits the PBPs. Interestingly, deletion of
the murM gene in S. pneumoniae eliminates indirect cross-
links from the PG and results in a complete loss of penicillin
resistance (Filipe et al., 2001). It has been proposed that the
changes to the PBP active site, which prevent b-lactam bind-
ing, may also alter the Lipid II substrate specificity such that
the PBPs bind branched Lipid II more tightly than unbranched732 Structure 29, 731–742, July 1, 2021Lipid II. MurM is therefore necessary but not sufficient for
resistance in clinical strains of S. pneumoniae, making it an
interesting target for the development of new inhibitors of anti-
microbial resistance (Filipe and Tomasz, 2000).
The cytoplasmic membrane of S. pneumoniae contains two
phospholipids, phosphatidylglycerol and cardiolipin (Trombe
et al., 1979; Pesakhov et al., 2007), where cardiolipin synthase
is responsible for generating cardiolipin from two molecules of
phosphatidylglycerol (Schlame, 2008). The proportion of cardio-
lipin and phosphatidylglycerol, as a percentage of the overall
membrane lipids, varies in S. pneumoniae between anaerobic
and aerobic growth conditions. Cardiolipin was found to
decrease from 15.3% to 8.3% while phosphatidylglycerol
increased from 12.7% to 16.3% in anaerobic conditions
compared with aerobic conditions (Pesakhov et al., 2007). The
peptidoglycan precursor, Lipid II, is tethered to the cell mem-
brane by virtue of its C55 Lipid II tail. Therefore, MurM acts on
its lipid substrate in close proximity to the cytoplasmic leaflet
Table 1. Summary of crystallographic data collection and






Unit cell a, b, c (Å), a, b, g () 45.01, 83.62, 133.93, 90.0,
90.0, 90.0
Space group P212121
Resolution (Å) 52.27–1.62 [1.66–1.62]
Observations 422,822 [29,596]






Completeness (%) 99.7 [99.8]
Refinement
Non-hydrogen atoms 3,397 (including 177 waters)
Rcryst
b 0.221 [0.262]
Reflections used 61,691 [4,531]
Rfree
c 0.262 [0.296]
Reflections used 3,294 [244]
Rcryst (all data)
b 0.222
Average temperature factor (Å2) 26
RMSDs from ideal values
Bonds (Å) 0.013
Angles () 1.5




The highest-resolution bin of data is indicated by square brackets.
Numbers in square brackets refer to values in the highest-resolution shell.
aRsym = SjSh

Ih;j  < Ih> =SjSh<Ih>, where Ih,j is the is the jth observation
of reflection h, and Ih is the mean intensity of that reflection.
bRcryst = SjjFobsj  jFcalc jj =SjFobsj, where Fobs and Fcalc are the
observed and calculated structure factor amplitudes, respectively.
cRfree is equivalent to Rcryst for a 4% subset of reflections not used in the
refinement (Br€unger, 1992).
dDPI refers to the diffraction component precision index (Cruick-
shank, 1999).
eAs calculated by MolProbity (Williams et al., 2008).
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OPEN ACCESSArticleof the cell membrane and is potentially influenced by membrane
phospholipid composition.
Previously, MurM inhibitors have been identified; however,
none have shown growth inhibition or any effect on penicillin
minimum inhibitory concentration, indicating that these com-
pounds cannot effectively cross the cytoplasmic membrane of
S. pneumoniae (Cressina et al., 2007, 2009). MurM has thus far
resisted extensive crystallization in our laboratory, and conse-
quently its X-ray-solved structure is not available. However, in
a related study we were able to solve the X-ray structure of the
isofunctional homolog of MurM from S. aureus (FemX), whichwe have used here as a template for homology modeling of
MurM. Using this MurM homology model, we have successfully
identified the Lipid II binding site and have used molecular dy-
namics (MD) simulations to investigate interactions between
MurM and both membrane phospholipids and its Lipid II sub-
strate (Witzke et al., 2016). We subsequently studied the effects
of thesemembrane-embedded phospholipids, on the enzymatic
activity of MurM in vitro, corroborating our in silico analysis.
These studies provide insights into the structure and activity of
MurM, providing a link between phospholipid membrane
composition and peptidoglycan architecture. This may be useful
for the development of chemical probes for these proteins and
has important implications for future studies on penicillin resis-
tance mechanisms in S. pneumoniae.
RESULTS
X-ray crystallography and structure determination of
S. aureus FemX
The crystal structure of S. aureus FemX was solved to a resolu-
tion of 1.62 Å, and the structure was deposited in the PDB with
accession number PDB: 6SNR. A summary of the data collection
and refinement statistics is given in Table 1.
The final solved structure of S. aureus FemX contains a glob-
ular domain and a coiled-coil domain. Similar to FemA (Benson
et al., 2002), the globular domain can be divided into two subdo-
mains. Each subdomain contains a central five-stranded mixed-
polarity b sheet surrounded by four a helices. Subdomain 1A
comprises residues 1–145 and 384–421 while subdomain 1B
comprises residues 146–234 and 298–383. Unfortunately, resi-
dues 403–421 were not present in the density. The coiled-coil
domain consists of two antiparallel a helices, comprising resi-
dues 235–297. FemX and FemA can be superimposed onto
each other with a root-mean-square deviation (RMSD) of
2.7 Å over 384 residues. Similarly to FemA, FemX has a deep
L-shaped channel of about 20 3 40 Å located alongside the
globular domain andmainly in subdomain 1B. This channel com-
prises a peptidoglycan precursor binding site which was previ-
ously identified in S. aureus FemA (Benson et al., 2002). The
identity of this peptidoglycan precursor binding site has been
further confirmed by crystallographic analysis of Weissella viri-
descens FemX complexed with substrates (Biarrotte-Sorin
et al., 2004).
Homology modeling of S. pneumoniae MurM
The structures of two MurM homologs, S. aureus FemA and W.
viridescens FemX, were solved previously by X-ray crystallog-
raphy (Benson et al., 2002; Fonvielle et al., 2013; Biarrotte-Sorin
et al., 2004). The S. aureus FemA structure was subsequently
used as a template for homology modeling of MurM by Fiser
et al. (2003). However, alignment of S. aureus FemA, S. aureus
FemX, S. pneumoniae MurM, and W. viridescens FemX (Fig-
ure S1) showed that S. aureus FemX possesses the highest
sequence identity to MurM and is also more functionally homol-
ogous toS. pneumoniaeMurM, as it appends the first amino acid
of the cross-bridge to the Lipid II precursor (Matsuhashi et al.,
1967; Schneider et al., 2004). In contrast, S. aureus FemA ap-
pends the second and third amino acid residues of the cross-
bridge to the a-amino group of a glycyl residue appended toStructure 29, 731–742, July 1, 2021 733
Figure 2. Cartoon representation of MurM
predicted structure
Fourteen a helices (red), 12 b sheets (yellow), and
unstructured regions (green). Best model obtained
based on SOAP and DOPE scores following ho-
mologymodeling usingMODELLERwithS. aureus
FemX as a template. The structure was rendered
in PyMOL (version 2.2.0).
ll
OPEN ACCESS Articlethe ε-amino group of the stem peptide L-lysyl residue of the Lipid
II precursor. Therefore, given the difficulties in obtaining MurM
crystals, we were motivated to solve the structure of its func-
tional homolog (S. aureus FemX) by X-ray crystallography to ac-
cess the structure of MurM in silico.
Using the structure of S. aureus FemX, we generated a homol-
ogy model for MurM, which consists of a globular domain
comprising two subdomains and a coiled-coil helical arm (Fig-
ure 2). Each subdomain comprises two twisted b-sheet cores
surrounded by a helices; subdomain 1A is formed of residues
1–153 and 382–401, while subdomain 1B is made up of residues
154–241 and 294–381. The coiled-coil domain comprises resi-
dues 242–293. While the MurM homology model presented
here is similar to the previous model (Fiser et al., 2003), the
RMSD of the two models is 3.8 Å over 368 residues, indicating
that there are some key structural differences, namely: loss of
N-terminal b1 and antiparallel b6/b13 from the previous model;
addition of a5 and b11/b12; and presence of an a-helical sec-
ondary structure proximal to the C-terminal end of this
MurM model.
Identification of a possible Lipid II binding site of MurM
Our MurMmodel revealed a binding pocket that was not present
in the previous model of MurM produced by Fiser et al. (2003).
Structural comparison betweenW. viridescens FemX co-crystal-
lized with its uridine diphosphate (UDP)-MurNAc-pentapeptide
substrate and this MurM model allowed identification of a Lipid
II binding site that corresponds to the peptidoglycan precursor
binding sites identified previously in S. aureus FemA and W. vir-
idescens FemX (Benson et al., 2002; Biarrotte-Sorin et al., 2004)
and in our structure of S. aureus FemX. When this MurM model
and theW. viridescens FemX were aligned and overlaid, the pro-
posed MurM binding site appeared to easily accommodate the
soluble UDP-MurNAc-pentapeptide substrate well (Figure 3A).
The following eight residues—Tyr103, Lys36, Asn38, Trp39,
Thr209, Arg211, Try215 and Tyr256—were independently pro-
posed to be involved in substrate binding in the peptidoglycan
precursor and tRNA liganded W. viridescens FemX structures
(Biarrotte-Sorin et al., 2004; Fonvielle et al., 2013). The corre-734 Structure 29, 731–742, July 1, 2021spondingMurM residues, defined as hav-
ing residues which have similar proper-
ties, and occupying a similar location
and orientation in physical space with
side chains facing the binding pocket,
were identified in the MurM structure as
Phe103, Lys35, Trp38, Arg215, and
Tyr219; therefore, these residues may
also be important for substrate binding
in MurM.Next, molecular docking using AutoDock Vina (Trott and Ol-
son, 2010) was conducted to independently investigate docking
of the Lipid II substrate to the MurMmodel we generated. Lipid II
is a large molecule that is, in general, unsuitable for molecular
docking studies. In addition, the lipid tail is embedded in the
membrane, and so is not itself available for binding to MurM.
Therefore, a truncated Lipid II molecule, composed of a methyl
capped diphospho GlcNAc-MurNAc-pentapeptide, was used
for these docking experiments (Figure S2).
When AutoDock Vina was allowed to search the entire protein
surface of MurM, all docking results returned were within the
identified binding site, indicating that there are no other suitable
binding sites on the protein. The search was then restricted to
the binding site, and the top ten results were obtained. The top
five results obtained all had identical binding affinities; however,
two of these docking orientations, where the phosphates are
located deep within the binding pocket, would be physically
impossible for the natural substrate (Lipid II) in vivo, since the
membrane-embedded prenyl lipid tail is appended via the phos-
phate. The remaining three docking orientations all orient the
phosphates close to the opening of the binding site with the
pentapeptide chain disappearing deep into the binding pocket.
The exact orientation of the pentapeptide chain is variable, indi-
cating that the binding site is spacious and that Lipid II may be
accommodated in a number of different possible orientations.
Figure 3B shows one conformation in which the docking of
truncated Lipid II is similar to the orientation of the soluble
UDP-MurNAc-pentapeptide from W. viridescens FemX overlaid
with MurM (Figure 3A), the remaining four substrate orientations
are shown in Figure S3. A key limitation of docking is that it con-
siders the protein as rigid; therefore, multiple substrate orienta-
tions may indicate that conformational changes within the bind-
ing site may occur upon substrate binding or during catalysis.
Additional docking studies were performed to further explore
the Lipid II binding pose in the putative MurM binding site and
establish whether this binding site shows specific affinity for
Lipid II or is indiscriminate between different lipid species. There-
fore, Lipid II, cardiolipin, phosphatidylglycerol, and phosphati-
dylethanolamine lipids (full molecules) were docked into the
Figure 3. Surface representation of MurM binding site
(A) MurM159 model aligned and overlaid with the UDP-MurNAc-pentapeptide substrate, which was co-crystallized with W. viridescens FemX.
(B) MurM159 model with truncated Lipid II docked in the binding site, using AutoDock Vina.
(C) MurM159 model with Lipid II in the binding site, from membrane simulations. Figures were created with PyMOL (version 2.2.0) and Chimera (version 1.13.1).
See also Figures S2 and S3.
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idues Lys35, Trp38, Phe103, Arg215, and Tyr219. We found
Lipid II bound into this site with atoms of the headgroup within
3 Å of the residues Lys35, Trp38, Phe215, and Arg219, and
with the Lipid II tail outside of this site. In stark contrast, the car-
diolipin and phosphatidylethanolamine headgroups did not
show any preference for this site; instead the binding poses
showed their tails inserted into the cavity. There was one binding
pose for phosphatidylglycerol whereby the phospholipid head-
group was in the putative binding site, although a portion of
the tail was also inside it; the remaining two phosphatidylglycerol
poses had the tails inserted into this cavity. For each lipid type
the top cluster of binding poses produced by HADDOCK2.4
(Van Zundert et al., 2016) were analyzed, and the top three bind-
ing poses for each lipid are shown in Figure S4.
Interactions between MurM and the lipid bilayer
Given the docking studies are performed in the absence of the
membrane environment, a set of coarse-grainedMD simulations
was next performed to establish the likelihood ofMurMbeing ori-
ented on the membrane such that the putative binding site is
available to Lipid II. MD simulations were used tomodel the inter-
actions of MurM with the lipid bilayer. Six independent coarse-
grained simulations were conducted for each of threemembrane
systems described in Table S1. In 16 of these simulation runs,
MurM readily associated with the membrane in <3 ms and its
orientation with respect to the membrane remained unchanged
for the remaining 2 ms (Figure S5). In addition, in the same mem-
brane leaflet as the peripheral MurM, more than 50% of Lipid II
molecules were located within 2 nm of the protein. MurM asso-
ciated with the membrane in a number of different orientations,
which can be classified into two groups: those in which the bind-
ing site predicted from docking studies is available for lipid bind-
ing and those in which it is not. Table 2 shows that in 18 unbiasedsimulations; MurM adhered to the membrane in 16 of the simu-
lations and of these, the binding site was available for Lipid II
binding in 11 and unavailable in only 5. In 3 of these 18 unbiased
simulations, MurM was oriented such that the Lipid II molecule
was located in the putative binding site, which demonstrates
that Lipid II is able to successfully enter this binding site even
on the short timescale of anMD simulation (Figure 4). Back map-
ping of one of these systems to all-atom resolution allowed the
binding site to be explored in more detail. Three independent
atomistic simulations each of 250 ns duration found Lipid II
located in the same binding site of MurM that was identified dur-
ing molecular docking of the truncated Lipid II substrate, and in
the co-crystal structure of UDP-MurNAc-pentapeptide with W.
viridescens FemX (Figure 3A). In both the molecular docking
and atomistic simulations, the Lipid II headgroup forms stable in-
teractions with Lys35, Trp38, Arg215, and Tyr219.
Similarly to the molecular docking findings, this MD simulation
shows that theMurMbinding site is flexible and allows the Lipid II
molecule to adopt awide variety of conformations (Figure 5). This
may suggest that binding of a second substrate or a large
conformational change may be required for catalysis.
Interactions between MurM and membrane
phospholipids
MD simulations were used to investigate the effects of mem-
brane phospholipids (cardiolipin and phosphatidylglycerol) on
MurM at the cytoplasmic membrane interface. To investigate
local lipid enrichment/depletion, we calculated two-dimensional
enrichment maps across the entire membrane and depletion-
enrichment (D-E) indices within 1.1 nm of MurM, as described
by Corradi et al. (2018) (see STAR Methods). A D-E index <0,
or an enrichment percentage <0%, indicated that the specified
lipid was depleted with respect to the bulk membrane composi-
tion. Figure 6 shows that upon association of MurM with theStructure 29, 731–742, July 1, 2021 735
Table 2. Summary of MurM adherence to and orientation on the








4 1 1 1
2 (12%
cardiolipin)
4 1 1 2
3 (16%
cardiolipin)
3 3 0 0
Orientation of MurM was categorized such that the putative binding site
was either available for Lipid II binding (facing/close to the membrane) or
unavailable for Lipid II binding (facing away from the membrane).
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OPEN ACCESS Articlecytoplasmicmembrane, therewas no effect on the distribution of
phosphatidylglycerol or phosphatidylethanolamine. However, in
membranes containing 8% or 16% cardiolipin, cardiolipin was
enriched at the MurM:membrane interface.
The importance of these observations was considered in vitro
by measuring the enzymatic activity of MurM in the presence of
varying concentrations of cardiolipin or phosphatidylglycerol.
These enzymatic studies show that cardiolipin activates MurM
while phosphatidylglycerol inhibits MurM in a concentration-
dependent manner. Figure 6E shows the enzymatic activation
of MurM with respect to cardiolipin concentration whereby a
9.1-fold activation of MurM was achieved, with 50% activation
occurring at 0.4 mM cardiolipin. Figure 6F shows that the activity
of MurM could be completely inhibited by phosphatidylglycerol,
with an IC50 of 0.2 mM. Furthermore, Hill coefficients of 2.7 ± 0.3
and 2.8 ± 0.2 for cardiolipin and phosphatidylglycerol, respec-
tively, indicate that both these phospholipids exhibit their effects
on MurM in a cooperative manner. Phosphatidylethanolamine,
used in the construction of the model pneumococcal membrane
to which MurM bound, when tested at a concentration of
0.72 mM, only slightly activated MurM activity by 0.32-fold
(duplicate determination with a difference of <10%). In compar-
ison, 0.72 mM cardiolipin activated MurM by 8-fold (Figure 6E).
Therefore, the impact of phosphatidylethanolamine on the
disposition of MurM relative to its interaction with Lipid II and
the phospholipid bilayer could be neglected.DISCUSSION
The crystal structure of S. aureus FemX has allowed us to
generate an improved homology model of MurM leading to the
identification of a putative Lipid II binding site. Fiser et al.
(2003) proposed a different MurM model and speculated about
an alternative binding site based on structural and functional
analogy between MurM and N-myristoyltransferase (NMT) pro-
teins. However, while the substrates of both NMT proteins and
MurM are lipids, they are contextually very different. The NMT
proteins are cytoplasmic proteins that contain a deep, narrow
pocket which is highly specific for the myristoyl fatty acyl chain
(Wright et al., 2010; Heuckeroth et al., 1988). In contrast, MurM
binds the disaccharide headgroup and pentapeptide side chain
of Lipid II, and the undecaprenyl C55 lipid tail is embedded in the
membrane. Despite similarities with NMT proteins, the substrate736 Structure 29, 731–742, July 1, 2021binding site we propose more closely resembles those ofW. vir-
idescens FemX, S. aureus FemX, and FemA.
The orientations of truncated Lipid II in docking studies and
Lipid II in MD simulations are strikingly similar to each other
and also the orientation of UDP-MurNAc-pentapeptide sub-
strate co-crystallized in W. viridescens FemX. This is consistent
with the observation that, although inefficient compared with
Lipid II, UDP-MurNAc pentapeptide is a MurM substrate (Lloyd
et al., 2008). In all cases, the diphosphates are near the surface
of the protein, and the protruding pentapeptide reaches into the
binding pocket with the third-position lysine on the left-hand side
of the binding pocket. In addition, previous studies suggest that
the height of the Lipid II headgroup is 19 Å (Ganchev et al., 2006),
and the binding pocket of this model was measured to be 15 Å.
Since the Lipid II headgroup is flexible and the binding site pro-
vides enough room for the substrate to bend, these measure-
ments are consistent. Together with our findings, this strongly
supports the identification of this cavity as the Lipid II binding
site and suggests that the Lipid II binds to MurM in an orientation
similar to that of W. viridescens FemX binding to its substrate.
Alanyl-phosphatidylglycerol synthase (PDB: 4v34), similarly to
MurM, also utilizes both lipid and alanyl-tRNAAla substrates (He-
becker et al., 2015). To successfully bring these two substrates
together for catalysis it possesses two binding sites, located
on opposite sides of the protein, which are connected by a chan-
nel. The protein itself provides a barrier between the hydropho-
bic lipid and the hydrophilic tRNA, such that they do not come
into close proximity with each other. The negatively charged sur-
face patch identified previously (Fiser et al., 2003) remains pre-
sent on this homology model of MurM and is located on the
opposite side of the protein with respect to the Lipid II binding
site, which is located within a positively charged surface patch.
This negative patch is unsuitable for the binding of negatively
charged tRNA, so it is unlikely that MurM shares the samemech-
anism of action as alanyl-phosphatidylglycerol synthase. The
negatively charged surface patch may, however, be important
for protein-protein interactions occurring either at the cell sur-
face or in the cytoplasm.
These modeling studies reveal that the stem peptide pro-
trudes perpendicular to the surface of the membrane into the
active site of MurM. Therefore, in order for alanyl-tRNAAla to
simultaneously interact with MurM, while it is located over its
lipid substrate the highly negatively charged hydrophilic tRNA
would have to be brought into close proximity with the negatively
charged phospholipid headgroups and/or the hydrophobic
phospholipid tails below them. Given that this would be a highly
unfavorable interaction, we propose an alternative ‘‘ping-pong’’
mechanism of action for MurM whereby MurM is initially amino-
acylated by alanyl- or seryl-tRNA in the cytoplasm before trans-
location to the cell membrane for aminoacyl transfer to Lipid II.
While the MurM is in the cytoplasm and not interacting with the
membrane, the positively charged patch, of the proposed Lipid
II binding site, may facilitate interaction with a polyanionic sub-
strate such as tRNA. Once this has occurred, subsequent inter-
action of the aminoacyl-MurM with the surface of the membrane
could accommodate the correct and catalytically productive
interaction of aminoacylated-MurM with Lipid II. Although
this proposed mechanism is at variance with the sequential
mechanism of catalysis proposed for W. viridescens FemX
Figure 4. Lipid II binding to the putative MurM binding site
(A), (B), and (C) show the three simulations whereby Lipid II was found to bind in the putativeMurM binding site. Each panel shows theMurM binding to Lipid II with
respect to the membrane (top), and an enlarged image of the MurM binding to Lipid II, with the membrane removed (bottom). MurM binding site residues K35,
W38, R215, and Y219 are depicted in yellow; the Lipid II headgroup and prenyl chain are rendered in red and blue, respectively.
See also Figure S1.
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hydrophilic nucleotide or polynucleotide derivatives in the
same cellular subcompartment and are therefore without bio-
physical impediment with regard to their proximity during catal-
ysis. Here, with regard to MurM, the chemical properties and
location of both substrates indicate an advantage to a mecha-
nism that avoids their simultaneous binding.
The pneumococcal peptidoglycan is heterogeneous with
respect to its composition of directly and indirectly crosslinked
stem peptides. It remains unclear as to whether the activity ofMurM, and therefore the generation of indirect crosslinks, is
distributed equally around the entire cell surface or whether it
is localized to specific sites. Phospholipids are known to be
involved in the spatial and temporal biochemistry of cells (Lin
et al., 2019), and cardiolipin was shown to be enriched at the
poles and septa of Escherichia coli and Bacillus subtilis, local-
izing specific membrane-associated proteins to these regions
(Bramkamp and Lopez, 2015). Our simulations indicate that,
while cardiolipin enrichment occurs within the membrane in the
presence of MurM, this phospholipid is not essential forFigure 5. Different conformations of Lipid II
inside MurM binding site
(A and B) MurM (gray) with Lipid II binding, colored
on a blue to white to red scale with respect to
simulation time, in system 5 (Table S2).




Figure 6. Interactions between MurM and membrane phospholipids
(A–C) Depletion-enrichment (D–E) indices for phosphatidylethanolamine (PE), phosphatidylglycerol (PG), and cardiolipin (CL) occurring within a 1.1-nm perimeter
of the MurM protein for (A) Systems 4 and 5 (molar ratio of 75% phosphatidylethanolamine and 25% phosphatidylglycerol), (B) Systems 6 and 7 (molar ratio of
76% phosphatidylethanolamine, 16% phosphatidylglycerol, and 8% cardiolipin), and (C) Systems 8 and 9 (molar ratio of 72% phosphatidylethanolamine, 12%
phosphatidylglycerol, and 16% cardiolipin). The D-E index was determined from 150 to 250 ns in 50-ns blocks for all repeats for a total of eight values per plot.
(D) Example of a D-E map with MurM at the membrane. White dots represent the center of geometry of each protein amino acid residue, and the percentage
enrichment of phospholipid is indicated by the color.
(E) Activation of MurM was calculated as the product of subtraction of MurM velocity in the absence of cardiolipin (v0(C)) from MurM velocity in the presence of
cardiolipin (v0(+C)) divided by v0(C) and was plotted versus cardiolipin concentration.
(F) Inhibition of MurM was calculated as [(v0(-PhG))  (v0(+PhG))]/v0(PhG) 3 100 (where PhG denotes phosphatidylglycerol) and was plotted versus phosphati-
dylglycerol concentration. Data were fitted as described in the text. GraphPad Prism (version 8.4.1) andMatplotlib (version 3.0.3) were used for data analysis and
figure preparation.
See also Figure S2.
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OPEN ACCESS Articlemembrane association of MurM to occur. Therefore, it remains
uncertain as to whether in vivo cardiolipin is highly concentrated
in patches in the membrane and is used to recruit MurM to that
location or whether association of MurM with the membrane
drives the enrichment of cardiolipin in the membrane.
Despite this uncertainty, we show that cardiolipin stimulates
the enzymatic activity of MurM, and while it is not clear if this
increased activity is a result of a direct effect on the protein or
the Lipid II substrate, or both, the spatial association of cardioli-
pin to the MurM protein suggests that at least some of this effect
may be due to direct interactions with the MurM protein.
Cardiolipin has previously been found to bind to and activate a
wide range of proteins including MurG (van den Brink-van der
Laan et al., 2003), rat liver protein kinase N (Morrice et al.,
1994; Peng et al., 1996), porcine heart AMP deaminase (Pur-
zycka-Preis and Zydowo, 1987), rat liver multi-catalytic protein-
ase (Ruiz de Mena et al., 1993), E. coli glycerol-3-phosphate
acyltransferase (Scheideler and Bell, 1989), E. coli dnaA (Seki-
mizu and Kornberg, 1988), and streptococcal hyaluronan syn-738 Structure 29, 731–742, July 1, 2021thases (Tlapak-Simmons et al., 1999a, 1999b, 2004; Weigel
et al., 2006; Tlapak-Simmons et al., 1998). This further supports
the contention that cardiolipin affects MurM activity by directly
interacting with MurM. Similar cardiolipin-mediated sigmoidal
stimulatory effects have been seen with other streptococcal
membrane proteins such as the hyaluronan synthases from
Streptococcus pyogenes and Streptococcus equisimilis (Tla-
pak-Simmons et al., 1999a, 1999b, 2004; Weigel et al., 2006).
In these examples, up to 16 cardiolipin molecules are believed
to associate with single hyaluronan synthase molecule (Tlapak-
Simmons et al., 1998).
We also show that phosphatidylglycerol inhibits the catalytic
activity of MurM and that the concentration of this lipid in the
membrane environment surrounding the MurM changes very lit-
tle. Therefore, the inhibitory effect of phosphatidylglycerol may
be exerted by altering the presentation of the Lipid II substrate
to MurM rather than by having a direct effect on the protein itself.
It is possible that in S. pneumoniae, as in E. coli and B. subtilis,
cardiolipin gathers in specific regions of the membrane, where
ll
OPEN ACCESSArticlein the pneumococcus it localizes and upregulates the activity of
MurM, resulting in higher levels of indirect crosslinking in these
regions.
While MurM alone is not sufficient for penicillin resistance, the
enzyme is crucial together with mosaic S. pneumoniae PBPs for
the generation of a highly resistant phenotype. Deletion ofmurM
from resistant strains resulted in a virtual abolition of penicillin
resistance that could not be restored by PBP DNA. Indeed, addi-
tional murM DNA from a resistant strain was required for full
expression of donor-level penicillin resistance (Filipe and Tom-
asz, 2000; Smith and Klugman, 2001). Given the importance of
MurM for penicillin resistance, the enrichment of cardiolipin at
the MurM:membrane interface which activates MurM, and the
inhibition of MurM activity by phosphatidylglycerol may regulate
the penicillin resistance phenotype imparted by MurM activity,
which may therefore be regulated by cardiolipin synthase activ-
ity. These findings have therefore revealed a crucial and hitherto
unexplored facet of penicillin resistance suggesting the involve-
ment of other areas of pneumococcal metabolism in the expres-
sion of clinical antibiotic resistance.
Conclusions
The MurM structural model presented in this work allowed
identification of the Lipid II binding site and the contextual pre-
sentation of this substrate to MurM. Furthermore, this work
characterized the impact of membrane phospholipids on
MurM at the MurM:membrane interface and may have spatial
mechanistic implications for the catalytic activity of this protein.
MD enabled the in silico investigation into MurM-membrane in-
teractions, which are often overlooked when studying enzymes
that act at the cytoplasmic membrane interface. The subse-
quent in vitro experiments on the importance of phospholipids
for MurM activity corroborate the in silico findings, supporting
the role of phospholipids as an important contributor to the
regulation of MurM at the membrane. These studies provide
insights into the structure of MurM, which may guide future
mutational studies and allow a more detailed analysis of the
structure-function relationship of this protein. This research
contributes important findings toward achieving a more com-
plete understanding of the role of MurM in pneumococcal peni-
cillin resistance mechanisms.
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Trombe, M.C., Lanéelle, M.A., and Lanéelle, G. (1979). Lipid composition of
aminopterin-resistant and sensitive strains of Streptococcus pneumoniae.
Effect of aminopterin inhibition. Biochim. Biophys. Acta 574, 290–300.
Trott, O., and Olson, A.J. (2010). AutoDock Vina: improving the speed and ac-
curacy of docking with a new scoring function, efficient optimization, and mul-
tithreading. J. Comput. Chem. 31, 455–461.
Vagin, A.A., Steiner, R.A., Lebedev, A.A., Potterton, L., McNicholas, S., Long,
F., and Murshudov, G.N. (2004). REFMAC5 dictionary: organization of prior
chemical knowledge and guidelines for its use. Acta Crystallogr. D Biol.
Crystallogr. 60, 2184–2195.
van den Brink-van der Laan, E., Boots, J.-W.P., Spelbrink, R.E., Kool, G.M.,
Breukink, E., Killian, J.A., and de Kruijff, B. (2003). Membrane interaction of
the glycosyl-transferase MurG: a special role for cardiolipin. J. Bacteriol.
185, 3773–3779.
Van Zundert, G., Rodrigues, J., Trellet, M., Schmitz, C., Kastritis, P., Karaca,
E., Melquiond, A., vanDijk, M., De Vries, S., and Bonvin, A. (2016). The
haddock2.2 web server: user-friendly integrative modeling of biomolecular
complexes. J. Mol. Biol. 428, 720–725.
Wang, J., Wolf, R.M., Caldwell, J.W., Kollman, P.A., and Case, D.A. (2004).
Development and testing of a general amber force field. J. Comput. Chem.
25, 1157–1174.
Wassenaar, T.A., Pluhackova, K., Bockmann, R.A., Marrink, S.J., and
Tieleman, D.P. (2014). Going backward: a flexible geometric approach to
reverse transformation from coarse grained to atomistic models. J. Chem.
Theor. Comput. 10, 676–690.Structure 29, 731–742, July 1, 2021 741
ll
OPEN ACCESS ArticleWeigel, P.H., Kyossev, Z., and Torres, L.C. (2006). Phospholipid dependence
and liposome reconstitution of purified hyaluronan synthase. J. Biol. Chem.
281, 36542–36551.
Williams, C.J., Headd, J.J., Moriarty, N.W., Prisant, M.G., Videau, L.L., Deis,
L.N., Verma, V., Keedy, D.A., Hintze, B.J., Chen, V.B., et al. (2008).
MolProbity: more and better reference data for improved all-atom structure
validation. Protein Sci. 27, 293–315.
Winter, G. (2010). xia2: an expert system for macromolecular crystallography
data reduction. J. Appl. Cryst. 43, 186–190.
Witzke, S., Petersen, M., Carpenter, T.S., and Khalid, S. (2016). Molecular dy-
namics simulations reveal the conformational flexibility of lipid II and its loose742 Structure 29, 731–742, July 1, 2021association with the defensin plectasin in the Staphylococcus aureus mem-
brane. Biochemistry 55, 3303–3314.
Wright, M.H., Heal, W.P., Mann, D.J., and Tate, E.W. (2010). Protein myristoy-
lation in health and disease. J. Chem. Biol. 3, 19–35.
Zapun, A., Philippe, J., Abrahams, K.A., Signor, L., Roper, D.I., Breukink, E.,
and Vernet, T. (2013). In vitro reconstitution of peptidoglycan assembly from
the Gram-positive pathogen Streptococcus pneumoniae. ACS Chem. Biol.
8, 2688–2696.
Zubay, G. (1962). The isolation and fractionation of soluble ribonucleic acid. J.
Mol. Biol. 4, 347–356.
ll
OPEN ACCESSArticleSTAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Bacterial and Virus Strains
E. coli BL21 Star (DE3): F- ompT hsdSB
(rB
- mB
-) gal dcm rne131 (DE3)
Invitrogen Cat# C601003
E. coli B834 (DE3) - F- ompT hsdSB
(rB
- mB
-) gal dcm met (DE3)
Novagen Cat# 69401
E.coli Rosetta 2 (DE3). F- ompT hsdSB(rB- mB-)
gal dcm (DE3) pRARE2 (CamR)
Novagen Cat# 71405
E. coli BL21 Star pRosetta2 (DE3) - F- ompT hsdSB
(rB- mB-) gal dcm rne131 pRARE (DE3)
Lloyd et al. (2008) N/A
E. coli C41 (DE3) (a derivative of BL21(DE3) [F_ ampT
hsdS8 (r8m8)gal dcm DE3]) pRIL (CamR)
Lloyd et al. (2008) N/A
E. coli B834 (DE3): pRosetta2 - F- ompT hsdSB (rB
- mB
-)
gal dcm met pRARE2 (DE3)
Novagen Cat# 69041
M. flavus (M. luteus) (Stanley130.21) NCIMB Cat# 8166
Chemicals, Peptides, and Recombinant Proteins
Poly(ethylene glycol) 8000 Fluka Cat# 81272
L-Alanine, [2,3-3H] Moravek Cat# MT-886
Lipid II (Lys) BACWAN/Lloyd et al. (2008) Cat# C55-LII-5K
Phosphatidylglycerol
L-alpha-Phosphatidyl-DL-glycerol sodium salt from
egg yolk lecithin, =99% (TLC), lyophilized powder
MERCK LIFE SCIENCE UK LTD Cat# P8318
Cardiolipin
Cardiolipin sodium salt from bovine heart, =98% (TLC),
lyophilized powder
MERCK LIFE SCIENCE UK LTD Cat# C0563
JCSG-plus crystallization screen Molecular Dimensions Cat# MD1-37
PACT premier crystallization screen Molecular Dimensions Cat# MD1-29
Morpheus crystallization screen Molecular Dimensions Cat# MD1-46
Cobalt TALON resin Takara Cat# 635502
Nickel- Chelating Sepharose Cytiva Cat# 17526801
Superdex 75 Size exclusion media Cytiva Cat# 17104404
Sephacryl S200 size exclusion media Cytiva Cat# 17058401
Selenomethionine Acros Organics Cat# 259960025
Tomato etch virus (TEV) Protease New England Biolabs Cat# P8112
BsaI New England Biolabs Cat# R0535S
Xho1 New England Biolabs Cat# R0146S
Hen egg white lysozyme MERCK LIFE SCIENCE UK LTD Cat# L6976
Deposited Data










(Continued on next page)
Structure 29, 731–742.e1–e6, July 1, 2021 e1
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Recombinant DNA
pRosetta 2 (purified from Escherichia coli
RosettaTM 2 (DE3))
Novagen Cat# 71405
pET28a(+) Novagen Cat# 69864
pET21b::MurM159 Lloyd et al. (2008) N/A
pET26b::alaRS Lloyd et al. (2008) N/A
pET28::FemX This paper N/A
Software and Algorithms
GraphPad Prism Version 8.4.1. GraphPad Soft-ware,
San Diego, CA, USA.
www.graphpad.com
Xia2 Winter (2010) https://xia2.github.io/
XDS package Kabsch (2010) http://xds.mpimf-heidelberg.mpg.de
SHELX suite Sheldrick (2010) https://www.shelxle.org/shelx/
eingabe.php
ARP/wARP Langer et al. (2008) https://www.embl-hamburg.de/ARP/
REFMAC Vagin et al. (2004) https://www2.mrc-lmb.cam.ac.uk/
groups/murshudov/content/refmac/
refmac.html
COOT Emsley et al. (2010) https://www2.mrc-lmb.cam.ac.uk/
personal/pemsley/coot/
MODELLER Eswar et al. (2006); Martı́-Renom
et al., 2000; sali and Blundell
(1993); Fiser et al. (2000)
https://salilab.org/modeller/
Chimera (Version 1.13.1) Pettersen et al., (2004) https://www.cgl.ucsf.edu/chimera/
Discrete Optimized Protein Energy (DOPE-HR) Shen and sali (2006)
Statistically Optimized Atomic Potentials (SOAP) Dong et al. (2013) https://github.com/salilab/SOAP
PyMOL (Version 2.2.0) Schrodinger, LLC. 2010.
The PyMOL Molecular
Graphics System, Version 2.1.0
https://pymol.org/2/#download
Avogadro2 software Hanwell et al. (2012) https://www.openchemistry.org/
downloads/
AutoDock Vina Trott and Olson (2010) http://vina.scripps.edu/
download.html
HADDOCK web server Van Zundert et al. (2016) https://bianca.science.uu.nl/
haddock2.4/
GROMACS package (Version 2018) Abraham et al. (2015) http://www.gromacs.org/
Auto-mated topology builder (ATB) web-interface Malde et al. (2011) https://atb.uq.edu.au/
PyCGTOOL Graham et al. (2017) https://pypi.org/project/pycgtool/
CHARMM-GUI web interface Jo et al. (2017) http://charmm-gui.org/
backward script Wassenaar et al. (2014) http://www.cgmartini.nl/index.php/
downloads/tools/240-backward
Particle mesh Ewald (PME) algorithm Darden et al. (1993) N/A
Visual Molecular Dynamics (VMD) Humphrey et al. (1996) https://www.ks.uiuc.edu/
Research/vmd/
ll
OPEN ACCESS ArticleRESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, David
Roper (David.Roper@warwick.ac.uk).
Materials availability
This study did not generate any new unique reagents. Plasmids will be available by Materials Transfer Agreement (MTA) request in
line with University of Warwick IP requirements.e2 Structure 29, 731–742.e1–e6, July 1, 2021
ll
OPEN ACCESSArticleData and code availability
No novel code was generated during this work. Modelling scripts and raw data are available from the authors upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
E. coli B834 (DE3) - F- ompT hsdSB (rB- mB-) gal dcmmet (DE3), referred to as E. coli B834 (DE3) in the method details section was
transformed with pRosetta2 to yield E. coli B834 (DE3): pRosetta2 - F- ompT hsdSB (rB
- mB
-) gal dcmmet (DE3) which was employed
as the expression host for selenomethionine substituted S. aureus FemX. E. coliC41 (DE3) (a derivative of BL21(DE3) [F_ ampT hsdS8
(r8m8)gal dcm DE3]) was transformed with pRIL (CamR)). The resulting transformant referred to as E. coli C41 (DE3)/pRIL in the
method details section was employed as the expression host for expression of S. pneumoniae (159) MurM. E. coli BL21 Star
(DE3): F- ompT hsdSB (rB
- mB
-) gal dcm rne131 (DE3) was transformed with pRosetta2 to yield E. coli BL21 Star pRosetta2 (DE3) -
F- ompT hsdSB (rB- mB-) gal dcm rne131 (DE3) referred to as E. coli BL21(DE3) star/pRosetta2 in the methods details section which
was utilized as the expression host for expression of S. pneumoniae (Pn16) alanyl-tRNAAla synthetase (AlaRS). Expression of sele-
nomethionine-labelled FemX was performed in M9 media supplemented with all 19 canonical amino acids and 40 mg mL1 [LA1] L-
selenomethionine in place in L-methionine. Expression of the remaining proteins were performed in luria broth. For all expression
experiments freshly transformed expression hosts were cultured shaken at 180–200 rpm at 37C in the presence of the appropriate
antibiotics (30 mg mL1 kanamycin, 30 mg mL1 chloroamphenicol for FemX; 50 mg mL1 carbenicillin, 30 mg mL1 chloroamphe-
nicol for MurM and 30mgmL1 kanamycin, 30mgmL1 chloroamphenicol for AlaRS) until mid-exponential phase (Optical density at
600 nm (OD600) = 0.4–0.6). At this point, cultures were supplemented with fresh antibiotics and protein expression was induced by 1
mM isopropyl-D-1-thiogalactopyranoside at 25C for 4 h. Micrococcus flavus (Synonymous with M. luteus) was cultured shaken at
200 rpm at 37C in tryptic soy broth to late exponential phase (OD600 of 4).
METHOD DETAILS
Cloning, overexpression and purification of S. aureus FemX
The S. aureus Mu50 FemX gene was amplified from chromosomal DNA using Oligonucleotides FemX forward:
TTTGCGGGTGGTCTCCCATGGAAAAGATGCATATC ACTAATCAGG and FemX Reverse: TTTGCGCTCGAGGCCCTGAAAATACAG
GTTTC TTTTCGTTTTAATTTACGAGATATTTTAATTTTAGC. The resulting PCR fragment was cleaved with BsaI and XhoI and cloned
into pET28 between theNcoI andXhoI restriction sites to create pET28::FemX, containing a Tobacco Etch Virus (TEV) protease cleav-
able C-terminal hexa-histidine tag. E. coli B834 (DE3) harbouring plasmid pRosetta2 (which supplies seven rare tRNAs to support
expression of genes in E. coli and derived from the Rosetta 2(DE3) strain) were transformed with pET28::FemX. Transformed
E. coli B834 (DE3) pRosetta2 were used to inoculate M9 media supplemented with 30 mg mL1 kanamycin, 30 mg mL1 chloroam-
phenicol, and 40 mg mL1 of each of the canonical amino acids [LA1] except L-methionine, which was replaced by 40 mg mL1
(Doublié, 1997). Transformants were cultured at 37C at 180 rpm until an optical density at 600 nm (OD600) of 0.4-0.6 was reached.
Protein expression was induced by 1 mM isopropyl-D-1-thiogalactopyranoside at 25C for 4 hours. Cells were harvested by centri-
fugation at 6,000 xg for 15 minutes and cell pellets containing 4-6 g of cells were resuspended in 20 mL of 50 mM sodium phosphate
pH 7.0, 1M NaCl and 2.5 mg.mL-1 lysozyme to which one tablet of Pierce EDTA free Protease Inhibitor was added. The cell suspen-
sion was incubated with slow rotation for 30minutes at 4Cbefore disruption using a Bandelin Sonopuls sonicator with 3 x 30 second
bursts at 70% power. The lysate was clarified by centrifugation at 50,000 xg at 4C for 30 minutes. FemX was then purified by im-
mobilised metal affinity chromatography (IMAC) using a 5 mL gravity fed column of cobalt Talon resin equilibrated with 50 mL of
50 mM sodium phosphate pH 7.0, 500 mM NaCl, 20% (v/v) glycerol (equilibration buffer) supplemented with 10 mM imidazole.
Once the 50,000 xg supernatant was loaded onto the column, it was eluted sequentially with 50 mL of equilibration buffer with
10 mM imidazole, 30 mL of equilibration buffer with 50 mM imidazole and 30 mL of equilibration buffer with 200 mM imidazole.
10 mL Fractions were analysed by SDS-PAGE and those containing FemX were pooled and concentrated, using a vivaspin 20 cen-
trifugal concentrator (10,000 molecular weight cut off (MWCO), as required. Size exclusion chromatography in 50 mM sodium phos-
phate pH 7.0, 500 mM NaCl and 20% (v/v) glycerol was used to further purify FemX on a Superdex 75 10/300 column. The histidine
tag was then removed from the FemX protein by digestion with histidine-tagged TEV protease at a molar ratio of 100:1 FemX : TEV
protease at 4C overnight. Cleaved and uncleaved protein were separated by a reverse IMAC following the procedure
described above.
FemX crystallisation and data collection
FemX was exchanged into 50 mM ethanolamine pH 10.0, 100 mM NaCl and 20% (v/v) glycerol, concentrated to 15 mg.mL-1 using a
vivaspin 20 centrifugal concentrator column with a 10,000 MWCO and screened for suitable crystallisation conditions using a
honeybee 963 crystallisation robot against JCSG plus, PACT primer and Morpheus crystallisation screens. Crystals obtained
from theMorpheus screen were used directly for data collection experiments, although crystallization conditions were further refined
to 0.12 M ethylene glycol, 0.1 MMES/imidazole pH 6.3 and 28% (w/v) ethylene glycol-PEG 8000. Crystals were frozen directly for X-
ray diffraction data experiments on the I04-1 beamline at the Diamond synchrotron (Didcot, UK) using a Pilatus 6M-F detector. Data
were processed automatically using Xia2 (Winter, 2010) to 1.62 Å. Molecular replacement was not successful so selenomethionine
containing FemX protein was produced and used to obtain FemX crystals (FemX-SeMet) in the same crystallisation conditions andStructure 29, 731–742.e1–e6, July 1, 2021 e3
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on the I02 beamline at the Diamond synchrotron (Didcot, UK) using a Pilatus 6M detector. All data were indexed, integrated and
scaled using the XDS package (Kabsch, 2010). All 10 of expected selenium atoms in the asymmetric unit were located and refined
by the SHELX suite (Sheldrick, 2010). These sites were used to obtain preliminary phases. The startingmodel was built by ARP/wARP
(Langer et al., 2008). This model was used to refine the higher resolution data. The structure was refined using iterative cycles of RE-
FMAC (Vagin et al., 2004) and model building/solvent addition with COOT (Emsley et al., 2010).
Cloning, Overexpression and Purification of S. pneumoniae(159) MurM
As described in Lloyd et al. (2008), theMurM allele of S. pneumoniae(159) was cloned with a C-terminal histidine tag into pET21b and
over-expressed in E. coli C41 (DE3)/pRIL. Cells were harvested by centrifugation and treated with 2.5 mg.mL-1 hen egg white lyso-
zyme prior sonication. MurMwas solubilised with 1MNaCl and fractionated between 25% and 50% of saturation ammonium sulfate
followed by purification by size exclusion chromatography with Sephacryl S-200 and by immobilized metal affinity chromatography
(IMAC) using cobalt Talon resin. The purity and identity of the final products of these purifications were assessed by SDS-PAGE.
Cloning, Overexpression and Purification of S. pneumoniae(Pn16) AlaRS
As described in Lloyd et al. (2008), the AlaRS allele of S. pneumoniae(Pn16) was cloned into pET26a and over-expressed in E. coli
BL21(DE3) star/pRosetta2 The soluble protein was purified using nickel-chelated Chelating sepharose, desalted and further purified
by anion exchange chromatography on a 0.98mlMonoQTM, column. The purity and identity of the final products of these purifications
were assessed by SDS-PAGE.
Preparation of MurM substrates
The substrates used for assays of MurM were prepared as follows:
Lipid II(Lys): The peptidoglycan intermediate Lipid II(Lys) (undecaprenyl pyrophosphoryl N-N-acetyl muramyl (N-acetyl glucosa-
minyl) L-alanyl-g-D-glutamyl-L-lysyl-D-alanyl-D-alanine) was prepared by re-capitulation of the peptidoglycan synthesis pathway as
described (Lloyd et al., 2008).
[3H]-Alanyl-tRNAAla:Micrococcus flavus tRNA was isolated from cell pellets ofM. flavus cultures grown to late exponential phase
by phenol extraction followed by isopropanol precipitation, anion exchange chromatography and ethanol precipitation as described
by Zubay (1962) as adapted by Lloyd et al. (2008). tRNAs were renatured in 2 mMMgCl2 at 60
C and aminoacylated with [2,3-3H]-L-
alanine S. pneumoniae (Pn16) AlaRS as described by Lloyd et al. (2008) and quantitated by liquid scintillation counting.
S. pneumoniae MurM enzymology
MurM was assayed as described by Lloyd et al. (2008) in duplicate in a final volume of 35 ml of 50 mM 3-(N-morpholino)-propane
sulphonic acid adjusted to pH 6.8, 30 mM KCl, 10 mM MgCl2, 1.5% (w/v) CHAPS (Assay Buffer), 1 mM DTT, 1 mM L-alanine,
10 mM Lipid II-Lys and 24.3 nM MurM. Reactions were initiated by the addition of 0.45 M [3H]-alanyl-tRNAAla (1000 cpm.pmol-1)
and were incubated at 37C for two minutes, over which time frame, product accumulation was linear with respect to time. Where
the impact of cardiolipin or phosphatidylglycerol on MurM activity was assessed, the required amounts of 10 mg/mL stocks of each
phospholipid in ethanol or chloroform/methanol (49:1) were dried down in the reaction vials the assays were to be performed in, and
solubilised by addition of assay buffer. Reactions were terminated by the addition of 35 ml of ice-cold 6 M pyridinium acetate pH 4.5
and 70 ml ice-cold n-butanol. The incubations were rapidly mixed and centrifuged for 5 minutes at 1C at 13,000 xg, after which time
the n-butanol phase was washed with 70 ml of water and then assayed for [3H]-Lipid II-L-Ala by liquid scintillation counting. Tritium
counts accumulated in control reactions performed without Lipid II(Lys) were subtracted from corresponding data acquired in the
presence of this substrate. MurM activities in the presence of phospholipid were related to the activity of the enzyme in the absence
of phospholipid and plotted as fold activation or percentage inhibition vs phospholipid concentration. The data were then fitted using




h + ½Cardiolipinh (Equation 1)% Inhibition =
100:½Phosphatidylglycerolh
IC50
h + ½Phosphatidylglycerolh (Equation 2)
Maximum activation and S0.5 (Activation) (Equation 1) corresponded to the degree of activation at infinite cardiolipin concentration
and the cardiolipin concentration required to elicit half maximal activation respectively. IC50 (Equation 2) corresponds to the phos-
phatidylglycerol concentration that elicited half maximal inhibition. For both equations, h denoted the Hill coefficient.
Computational studies overview
A number of computational techniques were used in this study, to assist the reader in understanding the logistics of these methods,
we have provided a summary flowchart (supplemental information: Figure S6).e4 Structure 29, 731–742.e1–e6, July 1, 2021
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Due to the natural ability of streptococci to undergo homologous recombination, S. pneumoniaeMurM genes are highly mosaic, and
so, in line with the enzymology studies, the MurM sequence used for homology modelling was that of S. pneumoniae MurM159. S.
pneumoniae MurM, S. aureus FemX (PDB ID: 6SNR) and FemA (PDB ID: 1LRZ), and Weissella viridescens FemX (PDB ID: 3GKR)
were aligned (supplemental information: Figure S1) by multiple sequence alignment using Clustal Omega to determine sequence
identity (Sievers et al., 2011).
The structure of S. aureus FemXwas used as the template for homologymodelling due to its high relatedness withMurM.S. aureus
FemX and MurM159 sequences were aligned, and using MODELLER (Eswar et al., 2006; Martı́-Renom et al., 2000; sali and Blundell,
1993; Fiser et al., 2000) a test model was generated to verify the validity of the template and the alignment. This model was evaluated
by computing its energy profile according to the DOPE-HR (high-resolution version of the Discrete Optimized Protein Energy) (Shen
and sali, 2006), smoothed via window averaging with a size of 15 residues. The profiles of template and model were compared (sup-
plemental information: Figure S7), and further refinement was conducted in the region between Lys230 and Pro299, as well as in all
loop regions. This optimisation was conducted by performing a very slow MD annealing on the selected regions, whilst maintaining
the remaining structure. The scoring of the resulting conformations was obtained via a function built specifically to evaluate the ge-
ometry of loops. For this step, 64 different base models were created and their secondary structure was refined independently 16
times. The resulting 1024 models were evaluated and ranked using DOPE-HR as well as the SOAP (Statistically Optimized Atomic
Potentials) (Dong et al., 2013). The 10 best scoringmodels for each score were selected and evaluated based on the number of phys-
ical constraint violations present.
The best model of MurM159 was aligned with the previously published MurM model (Fiser et al., 2003) orW. viridescens Femx ho-
mologues (Fonvielle et al., 2013; Biarrotte-Sorin et al., 2004) for visualisation and analysis in PyMOL (Version 2.1.0).
Molecular docking of truncated Lipid II to MurM
A truncated Lipid II substrate (supplemental information: Figure S2) was created for initial molecular docking simulations. The trun-
cated Lipid II was drawn in ChemDraw Professional (Version 17.1) and converted to a pdb file using Avogadro (Version 1.2.0). To
prepare the ligand file for docking, the protonation state in H2O at pH 7.4 was computed. Subsequently the equilibrium geometry
minimizing the potential energy was computed using the general amber force field (GAFF) (Wang et al., 2004) from within the Avoga-
dro2 software (Hanwell et al., 2012). Molecular docking was conducted using AutoDock Vina (Trott andOlson, 2010), for which pdbqt
files were generated from the pdb files of receptor model and ligands using AutoDock Tools (Morris et al., 2009). Initially the location
of the binding site was verified by providing the algorithm with a search space that included the entire protein. Docking was then
repeated by restricting the search space to the identified binding site, in order to obtain the final docked conformation.
Molecular docking of Lipid II, Cardiolipin, Phosphatidylglycerol and Phosphatidylethanolamine to the putative MurM
binding site.
Using the HADDOCK2.4 web server (Van Zundert et al., 2016), full length Lipid II, cardiolipin and phosphatidylglycerol and phospha-
tidylethanolamine were docked into the putative MurM binding site, where the binding site is defined by the residues Lys35, Trp38,
Phe103, Arg215 and Tyr219.
Coarse-grained molecular dynamics simulations
All coarse-grained simulations were carried out with the GROMACS package (Version 2018) and the Martini (Version 2.2) forcefield
(Abraham et al., 2015; de Jong et al., 2012). Simulations at the coarse-grained and atomstic resolutions were carried out at 313 K. For
coarse-grained simulations, a stochastic velocity rescale thermostat with a coupling constant of 1:0 ps controlled the temperature.
The coordinates of the MurM homology model were used to generate a coarse-grained model using the ‘martinise.py’ script (de
Jong et al., 2013). The protein was coarse grained to the ElNeDyn model (Periole et al., 2009) with an elastic network strength and
cutoff of 500 kJmol-1nm-2 and 0:9 nm, respectively. The Lipid II model for inclusion in the membrane was parameterised using a
united atommodel (Gromos 53a6) generated by the Auto-mated topology builder (ATB) web-interface (Malde et al., 2011). Following
this, the coarse-grained mapping was pursued iteratively, and the bonded terms were fitted with PyCGTOOL (Graham et al., 2017).
Since the pneumococcal membrane comprises a complex mixture of lipids, a simplified membrane composition was required for
the simulations. In order to elucidate the effects of phosphatidylglycerol and cardiolipin on MurM, a non-pneumococcal lipid, phos-
phatidylethanolamine, was used as the majority lipid. Simulations were conducted with three different membrane systems (supple-
mental information: Table S1). System 1 comprised phosphatidylethanolamine and phosphatidylglycerol in a molar ratio of 75% and
25% respectively, system 2 contained phosphatidylethanolamine, phosphatidylglycerol and cardiolipin in a molar ratio of 76%, 16%
and 8% respectively and system 3 comprised phosphatidylethanolamine, phosphatidylglycerol and cardiolipin at a molar ratio of
72%, 12% and 16% respectively. The membrane systems of size 16x16x11:5 nm were generated with the CHARMM-GUI
web interface (Jo et al., 2017). Each system was relaxed with a series of minimisation and equilibration steps with timesteps of
5-20 fs, for up to 30 ns. The equilibration steps utilised a semi-isotropic Berendsen barostat, with a 4:0 ps coupling constant
(Berendsen et al., 1984). Following equilibration, Lipid II molecules (10 in total) were added to each membrane. The systems were
then minimised and equilbriated (for 10 ns), followed by a 2 ms production run to ensure sufficient mixing of all the lipid components.
All production runs were carried out using a 10 fs timestep and a Parrinello-Rahman semi-isotropic barostat with a 12 ps coupling
constant (Parrinello and Rahman, 1981). The Lennard-Jones potential was cutoff using the Potential shift Verlet scheme at longStructure 29, 731–742.e1–e6, July 1, 2021 e5
ll
OPEN ACCESS Articleranges. The reaction field method (Tironi et al., 1995) was used for electrostatics calculations, with dielectric constants of 15 and in-
finity for charge screening in the short- and long-range regimes, respectively. The short-range cutoff for non-bonded and electro-
static interactions was 1:2 nm. Once lipid mixing was ensured, the size of each system was increased to 32 nm in the dimension
perpendicular to the membrane andMurMwas added in a random orientation around 8 nm above eachmembrane. Biologically rele-
vant salt concentrations (0.15 M NaCl) were added and 10% of the water molecules were changed to antifreeze particles to prevent
localised freezing during simulations. After minimisation and 1 ns of equilibration, during which the protein backbone was restrained
with 1000 kJmol-1nm-2 harmonic restraints, 6x5 ms production runs were generated per membrane composition (supplemental infor-
mation: Table S1).
All-atom molecular dynamics simulations
Atomistic simulations were conducted using the CHARMM36m forcefield (Huang et al., 2017). The Lipid II model used here was also
used in previous work (Witzke et al., 2016), while all other lipid models were obtained from the CHARMM-GUI membrane builder
module (Jo et al., 2008). For each coarse-grained membrane system, two repeats were chosen where: 1) the last frame of the
production run had a distinct orientation ofMurM, relative to themembrane 2)MurM adhered to themembrane surface (supplemental
information: Table S2). The last frame of the chosen coarse-grained repeats were then backmapped to the all-atommodel, using the
backward script (Wassenaar et al., 2014). Unfavourable ring conformers were corrected by carrying our minimisation and equilibra-
tion steps with dihedral restraints of 25000 kJmol-1rad-2 on key ring torsions. After the transformation was carried out, each system
was cropped in the z dimension to a height of 16:5 nm, to remove unnecessary H2O molecules.
Each system was minimised and equilibrated for a total of 1 ns, while the backbone of the protein was restrained with
1000 kJmol-1nm-2 harmonic restraints. Two production runs of 250 ns were carried out for each system. During the production
runs a timestep of 2 fs was used, and the pressure (1 bar) regulated with a semi-isotropic Parrinello-Rahman barostat, with a
coupling constant of 5:0 ps. The Lennard-Jones potential was cutoff with the Force-switch modifier from 1:0 to 1:2 nm. The short
range cutoff for the electrostatic interaction was also 1:2 nm and the Particle mesh Ewald (PME) algorithm (Darden et al., 1993)
was used for the long-range regime.
Analysis was carried out over the final 100 ns of each simulation, unless stated otherwise. All simulations were visualised using
Visual Molecular Dynamics (VMD) or PyMOL (Version 2.2.0) (Humphrey et al., 1996). Other analysis tools were written with a com-
bination of GROMACS tools and in house scripts, that utilised the python module MDAnalysis (Gowers et al., 2016). The deple-
tion/enrichment (D-E) indices were determined by first counting the number of lipids with a centre of geometry within 1.1 nm of
the protein and then comparing this number to the number expected in the bulk of the membrane, using the procedure described
by Corradi et al. (2018). The D-E index was obtained by dividing the lipid composition in the 1.1 nm shell around the protein by
the bulk membrane composition. Thus a D-E index >1 indicates enrichment, while a D-E index <1 indicates depletion. The D-E index
was determined for the last 100 ns of each simulation in 50 ns blocks for all repeats. For a givenmembrane composition, 8 D-E indices
were obtained for each lipid, from which the average and standard errors were calculated. The enrichment maps were generated by
first determining the 2D densitymap of themembrane using theGROMACS tool densmap. Following this, the enrichment percentage
was determined using the procedure described by Corradi et al. (2018). An enrichment percentage <0% indicated that local mem-
brane composition was depleted with respect to the bulk membrane composition. The code for the 2D enrichment maps and D-E
indices was reported in Shearer et al. (2019).
QUATIFICATION AND STATISTICAL ANALYSIS
Crystallographic statistics were calculated using software/programs as described in themethods, and values are reported in Table 1.
Enzyme assays were performed in duplicate, generating data that differed by no more than 10%. Average values were then plotted.
The standard errors of the fits of constants defining the relationships between the response of MurM to phospholipid and phospho-
lipid concentration according to equations 1 and 2 were calculated by GraphPad Prism (Version 8.4.1).e6 Structure 29, 731–742.e1–e6, July 1, 2021
